Satellos sets Duchenne trial endpoint after FDA talks, eyes 2027 results

Satellos Bioscience has set the endpoint for its Duchenne muscular dystrophy trial following discussions with the FDA, and expects results in 2027.

Detected & updated continuously · Source: Nebula